NCT02634970View on ClinicalTrials.gov

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Wet Age-related Macular Degeneration (Wet AMD)
Interventions
DRUG

Ranibizumab

0.5 mg, intravitreal injection

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY